Abstract 337P
Background
To determine the percentage of breast cancers detectable by fused diffusion-weighted imaging (DWI) using unenhanced magnetic resonance imaging (MRI) and abbreviated post-contrast-enhanced MRI.
Methods
Between October 2016 and October 2017, 194 consecutive women (mean age, 54.2 years; age range, 28-82 years) with newly diagnosed unilateral breast cancer who underwent preoperative 3.0 T breast MRI with DWI were evaluated. Both fused DWI and abbreviated MRI images were independently reviewed by two radiologists for the detection of index cancer (which showed the most suspicious findings in both breasts), location, lesion conspicuity, lesion type, and lesion size. Moreover, the relationship between cancer detection and histopathological results of surgical specimens were evaluated.
Results
Index cancer detection rates were comparable between fused DWI and abbreviated MRI (radiologist 1: 174/194 [89.7%] vs. 184/194 [94.8%], respectively, P = 0.057; radiologist 2: 174/194 [89.7%] vs. 183/194 [94.3%], respectively, P = 0.092). In both radiologists, abbreviated MRI showed a significantly higher lesion conspicuity than fused DWI (radiologist 1: 9.37 ± 2.24 vs. 8.78 ± 3.03, P < 0.001; radiologist 2: 9.16 ± 2.32 vs. 8.39 ± 2.93, P < 0.001). The κ value for the interobserver agreement of index cancer detection was 0.67 on fused DWI and 0.85 on abbreviated MRI. For lesion conspicuity, the intraclass correlation coefficients were 0.72 and 0.82 on fused DWI and abbreviated MRI, respectively. Among the histopathological factors, tumor invasiveness was associated with cancer detection on both fused DWI (P = 0.011) and abbreviated MRI (P = 0.004, radiologist 1), lymphovascular invasion was associated with cancer detection on abbreviated MRI (P = 0.032, radiologist 1), and necrosis was associated with cancer detection on fused DWI (P = 0.031, radiologist 2).
Conclusions
Index cancer detection was comparable between fused DWI and abbreviated MRI, although abbreviated MRI showed a significantly better lesion conspicuity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
292P - Unlocking the potential of circulating miRNAs in predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis
Presenter: Paola Tiberio
Session: Poster session 02
294P - Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
Presenter: Tong Wei
Session: Poster session 02
295P - ESR1, PGR, ERBB2, MKI67 single gene analysis in neoadjuvant-treated early breast cancer patients
Presenter: Rebekks Spiller
Session: Poster session 02
296P - Identification of metabolism-related therapeutic targets to improve response to neoadjuvant chemotherapy in early breast cancers
Presenter: Françoise Derouane
Session: Poster session 02
297P - Prognostic and predictive impact of NOTCH1 in early breast cancer
Presenter: Julia Engel
Session: Poster session 02
298P - Association of luminal-androgen receptor (LAR) subtype with low HER2 in triple-negative breast cancer
Presenter: Lee Min Ji
Session: Poster session 02
299P - Single-cell transcriptomic analysis reveals specific luminal and T cell subpopulations associated with response to neoadjuvant therapy in early-stage breast cancer
Presenter: Xiaoxiao Wang
Session: Poster session 02
300P - Correlation of PD-L1 protein and mRNA expression and their prognostic impact in triple-negative breast cancer
Presenter: Kathleen Schüler
Session: Poster session 02
301P - Epigenetic modifications of IL-17 gene in patients with early breast cancer and healthy controls
Presenter: Ljubica Radmilovic Varga
Session: Poster session 02
302P - Clinicopathological features and outcomes of pregnancy associated breast cancer: Case control study -single institution experience
Presenter: Nashwa Kordy
Session: Poster session 02